{"url_path":"/sec/atai/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/2081043/0001193125-26-219412-index.html","accession_number":"0001193125-26-219412","cik":"0002081043","ticker":"ATAI","issuer_name":"AtaiBeckley Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2081043/0001193125-26-219412-index.html","primary_entity_key":"0002081043","primary_entity_name":"AtaiBeckley Inc."},"word_count":464,"has_tables":true,"body_markdown":"10-Q\n\n--12-31Q1false0002081043http://fasb.org/us-gaap/2025#OperatingLeaseRightOfUseAssethttp://fasb.org/us-gaap/2025#OperatingLeaseRightOfUseAssethttp://fasb.org/us-gaap/2025#OperatingLeaseLiabilityNoncurrenthttp://fasb.org/us-gaap/2025#OperatingLeaseLiabilityNoncurrent0002081043us-gaap:CommonStockMember2025-02-012025-02-280002081043atai:CustomerOneMemberus-gaap:SalesRevenueNetMemberatai:ResearchAndDevelopmentServicesRevenueMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:EMP-01ExpensesMember2026-01-012026-03-310002081043atai:BeckleyPsytechLimitedMember2025-11-052025-11-050002081043atai:HsopSharesMemberatai:HsopPlanMember2026-03-310002081043atai:SeriesCSharesMember2025-04-300002081043us-gaap:CommonStockMemberatai:June2025PIPEFinancingMember2025-06-020002081043atai:TwoThousandAndEighteenConvertiblePromissoryNotesMember2025-01-012025-03-310002081043us-gaap:RestrictedStockUnitsRSUMember2026-03-310002081043atai:RoyaltyLiabilitiesMember2026-03-310002081043atai:RoyaltyLiabilitiesMember2025-12-310002081043atai:GabaTherapeuticsIncMember2025-01-012025-03-310002081043us-gaap:NoncontrollingInterestMember2025-03-310002081043atai:InternalUseSoftwareMember2025-12-310002081043atai:IntelgenxCorpMember2026-03-310002081043us-gaap:RestrictedStockUnitsRSUMemberatai:BeckleyPsytechMember2026-03-310002081043atai:ContingentConsiderationLiabilityRelatedPartiesMember2024-12-310002081043us-gaap:NoncontrollingInterestMember2025-01-012025-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:AccountingAndTaxFeesMember2025-01-012025-03-310002081043atai:HerculesLoanAgreementMember2026-03-310002081043atai:OtherSubsidiaryEquityPlansMemberus-gaap:GeneralAndAdministrativeExpenseMemberatai:OptionsAndRestrictedStockAwardsMember2026-01-012026-03-310002081043us-gaap:RetainedEarningsMember2025-12-310002081043us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002081043us-gaap:FairValueMeasurementsRecurringMember2025-12-310002081043atai:RizafilmLLCLicenseAndSupplyAgreementMember2026-01-012026-03-310002081043atai:GabaTherapeuticsIncMember2025-12-310002081043atai:UnderwritingAgreementMember2025-10-012025-10-310002081043us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-3100020810432025-01-012025-03-310002081043atai:TwentyTwentyIncentivePlanMember2025-01-012025-03-310002081043us-gaap:EmployeeStockMemberatai:BeckleyPsytechLimitedMember2025-11-052025-11-050002081043us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310002081043us-gaap:FairValueMeasurementsRecurringMember2026-03-3100020810432025-01-012025-09-300002081043atai:OTFTechnologyMember2025-12-310002081043atai:CompassPathwaysPlcMember2026-03-310002081043us-gaap:EmployeeSeveranceMember2025-01-012025-03-310002081043atai:AmandalaNeuroLimitedMember2026-01-012026-03-310002081043atai:June2025PIPEFinancingMember2026-01-012026-03-310002081043us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002081043country:DEus-gaap:MachineryAndEquipmentMember2026-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:OtherExpensesMember2025-01-012025-03-310002081043atai:GabaTherapeuticsIncMember2020-12-310002081043us-gaap:CommonStockMember2025-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2026-01-012026-03-310002081043us-gaap:NoncontrollingInterestMember2024-12-310002081043us-gaap:CommonStockMember2025-02-280002081043atai:OtherSubsidiaryEquityPlansMemberus-gaap:ResearchAndDevelopmentExpenseMemberatai:OptionsAndRestrictedStockAwardsMember2026-01-012026-03-310002081043us-gaap:StockCompensationPlanMember2026-01-012026-03-310002081043atai:UnvestedStockOptionsMemberatai:PerformanceObligationsMember2026-03-310002081043atai:ContingentConsiderationLiabilityRelatedPartiesMember2026-03-310002081043atai:PerceptionMember2024-12-310002081043atai:ServiceAndPerformanceBasedOptionsMemberatai:TwoThousandAndTwentyIncentivePlanMember2025-01-012025-12-310002081043atai:AmandalaNeuroLimitedNotesReceivableMember2025-11-300002081043us-gaap:WarrantMemberatai:June2025PIPEFinancingMember2025-06-022025-06-020002081043us-gaap:LeaseholdImprovementsMember2026-03-310002081043atai:InnoplexusAgMemberatai:InnoplexusSpaMember2026-01-012026-03-310002081043us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:DepreciationMember2025-01-012025-03-310002081043atai:AmandalaNeuroLimitedMember2026-03-310002081043atai:ResearchAndDevelopmentServicesRevenueMember2025-01-012025-03-310002081043atai:GabaTherapeuticsIncMember2026-03-3100020810432025-01-012025-12-310002081043atai:OtherProgramsExpensesMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-01-012025-03-310002081043us-gaap:WarrantMemberatai:SubscriptionAndShareholdersAgreementMember2024-05-012024-05-310002081043us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310002081043atai:ContingentConsiderationLiabilityMember2026-03-310002081043atai:ResearchAndDevelopmentServicesRevenueMember2025-01-012025-03-310002081043us-gaap:ParentMember2025-01-012025-03-310002081043us-gaap:StockCompensationPlanMember2025-01-012025-03-310002081043atai:GBelBucaManufacturingContractMember2025-12-310002081043atai:June2025PIPEFinancingMember2025-12-310002081043atai:BeckleyPsytechLimitedMember2025-10-3100020810432025-11-012025-11-300002081043us-gaap:CommonStockMember2024-12-310002081043atai:BeckleyPsytechLimitedMember2025-10-232025-10-230002081043us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-3100020810432025-05-310002081043us-gaap:RestrictedStockMember2025-01-012025-03-310002081043us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002081043us-gaap:AdditionalPaidInCapitalMember2025-12-310002081043atai:OTFTechnologyMemberus-gaap:ResearchAndDevelopmentExpenseMember2026-03-3100020810432026-01-012026-03-310002081043atai:BeckleyPsytechMember2026-03-310002081043atai:OtherSubsidiaryEquityPlansMemberus-gaap:GeneralAndAdministrativeExpenseMemberatai:OptionsAndRestrictedStockAwardsMember2025-01-012025-03-310002081043atai:SeriesCSharesMemberatai:BeckleyPsytechMember2026-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:DepreciationMember2026-01-012026-03-310002081043us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310002081043us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310002081043atai:MarketBasedConditionsMember2026-03-310002081043us-gaap:RestrictedStockMemberatai:TwentyTwentyIncentivePlanMember2026-01-012026-03-3100020810432025-03-310002081043atai:PsileraAcquisitionMember2026-01-012026-03-310002081043atai:BeckleyPsytechLimitedMemberus-gaap:CommonStockMember2025-11-052025-11-050002081043us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310002081043atai:BeckleyPsytechAdditionalWarrantsMember2025-03-310002081043atai:OtherExpensesNetMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2026-01-012026-03-310002081043atai:FounderMemberatai:AtaiFormationMember2025-12-310002081043us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2026-03-310002081043atai:BeckleyPsytechLimitedMember2025-04-300002081043atai:BeckleyPsytechLimitedMember2026-03-310002081043atai:NewNVNotesConversionFeatureMember2025-01-012025-03-310002081043atai:OtherMember2025-01-012025-12-310002081043atai:InnoplexusAgMemberatai:GabaTherapeuticsIncMember2026-03-310002081043atai:AtaiEsopMember2026-01-012026-03-310002081043us-gaap:InProcessResearchAndDevelopmentMember2026-03-310002081043us-gaap:ResearchAndDevelopmentExpenseMember2025-10-012025-10-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:DiscoveryNon-HallucinogenicExpensesMember2026-01-012026-03-310002081043us-gaap:RestrictedStockMember2025-01-012025-03-310002081043srt:MaximumMember2018-11-300002081043atai:StockPurchaseAndFrameworkAgreementMemberatai:DemerxMember2025-12-310002081043us-gaap:CommonStockMember2025-12-310002081043atai:June2025PIPEFinancingMember2025-06-020002081043atai:InnoplexusAgMember2026-03-310002081043us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002081043us-gaap:FurnitureAndFixturesMember2026-03-310002081043us-gaap:RetainedEarningsMember2025-01-012025-03-310002081043us-gaap:RetainedEarningsMember2025-03-310002081043atai:BeckleyPsytechLimitedMember2025-01-012025-12-310002081043atai:GBelBucaManufacturingContractMemberus-gaap:ResearchAndDevelopmentExpenseMember2026-03-3100020810432026-05-0800020810432025-02-012025-02-280002081043atai:PsileraAcquisitionMember2025-02-280002081043atai:AtaiLifeSciencesN.v.Member2023-12-310002081043us-gaap:InProcessResearchAndDevelopmentMember2025-01-012025-12-310002081043atai:CompassPathwaysPlcMember2025-01-012025-03-310002081043atai:TwoThousandAndTwentyIncentivePlanMember2026-01-012026-03-310002081043us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMemberatai:ContingentConsiderationLability-RelatedPartiesMemberatai:MeasurementInputProbabilityOfTheMilestoneMemberatai:DemerxMember2025-12-310002081043atai:BeckleyPsytechLimitedMemberatai:ThirdPartyMemberus-gaap:CommonStockMember2025-11-052025-11-050002081043atai:CustomerOneMemberatai:ResearchAndDevelopmentServicesRevenueMember2026-01-012026-03-310002081043atai:OtherSubsidiaryEquityPlansMember2026-01-012026-03-310002081043atai:SharePurchaseDeedMemberatai:BeckleyPsytechLimitedMemberatai:SeriesCPreferredSharesMember2024-01-030002081043us-gaap:CommonStockMember2026-01-012026-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:EMP-01ExpensesMember2025-01-012025-03-310002081043atai:GBelBucaManufacturingContractMember2025-01-012025-12-310002081043us-gaap:MeasurementInputDiscountRateMember2025-12-310002081043atai:TwoThousandAndTwentyOneIncentiveAwardPlanMember2026-03-310002081043atai:BeckleyPsytechLimitedMemberatai:AdditionalWarrantsMember2024-01-030002081043atai:ContingentConsiderationLiabilityMember2026-01-012026-03-310002081043atai:RizafilmMemberatai:SupplyAgreementMember2025-01-012025-01-310002081043us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMemberatai:ContingentConsiderationLability-RelatedPartiesMemberatai:DemerxMembersrt:MaximumMember2025-12-310002081043atai:July2025PIPEFinancingMember2025-07-010002081043atai:ResearchAndDevelopmentServicesRevenueMember2026-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:BPL-003ExpensesMember2026-01-012026-03-310002081043atai:HsopPlanMember2026-03-310002081043us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002081043atai:EscrowAgreementMember2024-10-310002081043us-gaap:RestrictedStockMember2026-01-012026-03-310002081043atai:InnoplexusAgMember2020-12-3100020810432026-03-310002081043atai:BeckleyPsytechMember2025-11-052025-11-050002081043us-gaap:ParentMember2024-12-310002081043atai:OTFTechnologyMember2025-01-012025-12-310002081043us-gaap:WarrantMemberatai:June2025PIPEFinancingMember2025-06-020002081043us-gaap:NoncontrollingInterestMember2026-03-310002081043atai:BeckleyPsytechAcquisitionMember2024-10-310002081043atai:AmendedGabaPspaMemberus-gaap:SeriesAPreferredStockMemberus-gaap:CommonStockMemberatai:GabaTherapeuticsIncMember2026-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:ResearchAndDevelopmentServicesRevenueMember2025-01-012025-03-310002081043us-gaap:ParentMember2026-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-01-012025-03-310002081043us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:InsuranceFeesMember2026-01-012026-03-310002081043atai:HsopSharesMemberatai:HsopPlanMember2025-01-012025-03-310002081043atai:OtherSubsidiaryEquityPlansMemberatai:OptionsAndRestrictedStockAwardsMemberus-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310002081043atai:GabaTherapeuticsIncMember2026-01-012026-03-310002081043atai:LegalIntellectualPropertyFeesMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2026-01-012026-03-310002081043atai:AmandalaNeuroLimitedMember2025-10-3100020810432025-12-310002081043atai:AtaiEsopMember2025-01-012025-03-310002081043atai:PsileraAcquisitionMemberus-gaap:ServiceOtherMember2026-01-012026-03-310002081043atai:BeckleyPsytechLimitedMembersrt:MaximumMember2025-11-052025-11-050002081043us-gaap:GeneralAndAdministrativeExpenseMemberatai:MrAngermayerMemberatai:ConsultingAgreementMember2025-01-012025-03-310002081043atai:BeckleyPsytechLimitedMemberatai:SubscriptionAndShareholdersAgreementMemberatai:SeriesCPreferredSharesMember2024-01-030002081043atai:ContingentConsiderationLiabilityRelatedPartiesMember2025-03-310002081043us-gaap:RetainedEarningsMember2024-12-310002081043atai:RizafilmMemberatai:SupplyAgreementMember2025-01-012025-03-310002081043atai:SeriesCSharesMember2024-10-310002081043atai:BeckleyPsytechLimitedMember2025-01-012025-03-310002081043us-gaap:ManufacturingFacilityMembercountry:CA2025-05-310002081043us-gaap:InProcessResearchAndDevelopmentMember2025-12-310002081043atai:July2025PIPEFinancingMemberus-gaap:CommonStockMember2025-07-010002081043atai:RecognifyLifeSciencesInc.Member2025-01-012025-12-310002081043atai:RecognifyMember2026-03-310002081043atai:CompassPathwaysPlcMemberatai:AmericanDepositaryShareMember2026-01-012026-03-310002081043atai:EleusisHoldingsLimitedMember2026-03-310002081043atai:RizafilmMemberatai:SupplyAgreementMember2026-01-012026-03-310002081043atai:AmandalaNeuroLimitedNotesReceivableMember2026-03-310002081043srt:MaximumMember2020-10-310002081043atai:RestrictedStockUnitsSubjectToLock-UpMember2026-01-012026-03-310002081043atai:TwoThousandTwentyFiveRestructuringMember2026-03-310002081043us-gaap:GeneralAndAdministrativeExpenseMember2025-10-012025-10-310002081043atai:GerdKochendoerferMember2026-01-012026-03-310002081043atai:RecognifyMember2025-12-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:DiscoveryNon-HallucinogenicExpensesMember2025-01-012025-03-310002081043atai:UnderwritingAgreementMemberus-gaap:CommonStockMember2025-10-012025-10-310002081043us-gaap:GeneralAndAdministrativeExpenseMemberatai:MrAngermayerMemberatai:ConsultingAgreementMember2026-01-012026-03-310002081043atai:AtaiLifeSciencesN.v.Member2024-04-300002081043atai:RestrictedStockUnitsSubjectToLock-UpMember2025-01-012025-03-310002081043us-gaap:GeneralAndAdministrativeExpenseMemberatai:OptionsAndRestrictedStockAwardsMemberatai:AtaiEsopMember2026-01-012026-03-310002081043us-gaap:PreferredStockMember2025-12-300002081043us-gaap:AdditionalPaidInCapitalMember2025-03-310002081043atai:BeckleyPsytechLimitedMemberatai:DeferredSharesMember2024-01-050002081043atai:CompassPathwaysPlcMember2025-12-3100020810432025-05-012025-05-310002081043us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310002081043atai:VestedStockOptionsMember2026-01-012026-03-310002081043us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002081043us-gaap:CommonStockMemberatai:July2025PIPEFinancingMember2025-07-012025-07-010002081043atai:NewNVNotesConversionFeatureMember2025-03-310002081043atai:ResearchAndDevelopmentServicesRevenueMember2026-01-012026-03-310002081043us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002081043us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002081043atai:PerceptionMember2025-12-3100020810432025-08-012025-08-310002081043atai:PsileraAcquisitionMember2026-03-310002081043atai:FounderMemberatai:AtaiFormationMember2026-03-310002081043atai:ContingentConsiderationLiabilityMember2024-12-310002081043atai:GabaTherapeuticsIncMember2025-12-310002081043atai:OtherSubsidiariesEquityPlanMember2026-01-012026-03-310002081043atai:AtaiLifeSciencesN.v.Member2025-01-012025-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:InsuranceFeesMember2025-01-012025-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:BPL-003ExpensesMember2025-01-012025-03-310002081043atai:BeckleyPsytechLimitedMember2025-06-022025-06-020002081043atai:RizafilmLLCLicenseAndSupplyAgreementMember2025-01-012025-03-310002081043atai:ServiceAndPerformanceBasedOptionsMemberatai:TwoThousandAndTwentyIncentivePlanMember2026-01-012026-03-310002081043us-gaap:NoncontrollingInterestMember2026-01-012026-03-310002081043atai:BeckleyPsytechLimitedMember2026-01-012026-03-310002081043atai:InternalUseSoftwareMember2025-01-012025-12-310002081043us-gaap:FurnitureAndFixturesMember2025-12-3100020810432025-10-012025-10-310002081043atai:PerceptionMember2025-01-012025-03-310002081043atai:PerceptionMember2025-03-310002081043atai:BeckleyPsytechLimitedMemberatai:SubscriptionAndShareholdersAgreementMember2026-01-012026-03-310002081043us-gaap:RetainedEarningsMember2026-03-310002081043atai:July2025PIPEFinancingMember2025-12-310002081043us-gaap:RestrictedStockUnitsRSUMember2025-12-310002081043atai:InternalUseSoftwareMember2026-03-310002081043us-gaap:NoncontrollingInterestMember2025-12-310002081043us-gaap:GeneralAndAdministrativeExpenseMemberatai:OptionsAndRestrictedStockAwardsMemberatai:AtaiEsopMember2025-01-012025-03-310002081043us-gaap:RestrictedStockMemberatai:TwentyTwentyIncentivePlanMember2026-03-310002081043us-gaap:ConvertibleDebtSecuritiesMember2026-01-012026-03-310002081043atai:AtaiLifeSciencesN.v.Member2025-01-012025-09-300002081043us-gaap:CommonStockMember2026-03-310002081043atai:LegalIntellectualPropertyFeesMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-01-012025-03-310002081043atai:InternalUseSoftwareMemberus-gaap:ResearchAndDevelopmentExpenseMember2026-03-310002081043us-gaap:MachineryAndEquipmentMember2025-12-310002081043atai:Pre-FundedWarrantsMember2026-01-012026-03-310002081043atai:BeckleyPsytechLimitedMemberatai:SeriesCWarrantsMember2024-01-030002081043atai:BeckleyPsytechAcquisitionMember2025-04-300002081043us-gaap:ParentMember2026-01-012026-03-310002081043atai:UnvestedStockOptionsMember2026-03-310002081043us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:AccountingAndTaxFeesMember2026-01-012026-03-310002081043us-gaap:ValuationTechniqueDiscountedCashFlowMemberatai:ContingentConsiderationLability-RelatedPartiesMemberatai:MeasurementInputProbabilityOfTheMilestoneMemberatai:DemerxMembersrt:MaximumMember2025-12-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:PersonnelAndEmployeeRelatedExpensesMember2025-01-012025-03-310002081043us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMemberatai:ContingentConsiderationLability-RelatedPartiesMemberatai:MeasurementInputProbabilityOfTheMilestoneMemberatai:DemerxMember2026-03-310002081043atai:StockPurchaseAndFrameworkAgreementMemberatai:DemerxMember2023-10-012023-10-310002081043atai:HsopSharesMemberatai:HsopPlanMember2026-01-012026-03-310002081043atai:Pre-FundedWarrantsMember2025-01-012025-03-310002081043us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310002081043atai:TwoThousandAndEighteenConvertiblePromissoryNotesMember2026-01-012026-03-310002081043atai:BeckleyPsytechAdditionalWarrantsMember2024-12-310002081043atai:SubscriptionAgreementsMemberatai:Pre-FundedWarrantsMember2026-01-012026-03-310002081043atai:TwoThousandTwentyFiveRestructuringMember2025-12-310002081043atai:RecognifyLifeSciencesInc.Member2026-01-012026-03-310002081043atai:VLS-01ExpensesMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2026-01-012026-03-310002081043atai:BeckleyPsytechAdditionalWarrantsMember2025-01-012025-03-310002081043atai:OtherProgramsExpensesMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2026-01-012026-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:NonCashShareBasedCompensationExpensesMember2025-01-012025-03-310002081043atai:AmandalaNeuroLimitedMember2025-12-310002081043atai:UnvestedStockOptionsMemberatai:OneToTwoYearServicePeriodMember2026-03-310002081043us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMemberus-gaap:MeasurementInputDiscountRateMemberatai:ContingentConsiderationLability-RelatedPartiesMemberatai:DemerxMember2025-12-310002081043us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002081043us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002081043atai:ContingentConsiderationLiabilityMember2025-03-310002081043atai:OtherExpensesNetMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-01-012025-03-310002081043atai:HsopOptionsToPurchaseCommonStockMember2025-01-012025-03-310002081043us-gaap:RetainedEarningsMember2026-01-012026-03-310002081043us-gaap:CommonStockMemberatai:June2025PIPEFinancingMember2025-06-022025-06-020002081043us-gaap:MeasurementInputDiscountRateMember2026-03-3100020810432025-02-280002081043atai:ContingentConsiderationLiabilityMember2025-01-012025-03-310002081043atai:GerdKochendoerferMember2026-03-310002081043atai:InnoplexusSpaMember2026-01-012026-03-310002081043atai:TwentyTwentyIncentivePlanMember2026-03-310002081043us-gaap:MachineryAndEquipmentMember2026-03-310002081043atai:OtherSubsidiaryEquityPlansMember2025-01-012025-03-310002081043atai:July2025PIPEFinancingMember2025-07-012025-07-010002081043us-gaap:AdditionalPaidInCapitalMember2026-03-310002081043atai:HsopSharesMemberatai:HsopPlanMember2025-12-310002081043atai:HsopOptionsToPurchaseCommonStockMember2026-01-012026-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:NonCashShareBasedCompensationExpensesMember2026-01-012026-03-310002081043us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberatai:ContingentConsiderationLability-RelatedPartiesMemberatai:DemerxMember2026-03-310002081043us-gaap:AdditionalPaidInCapitalMember2024-12-310002081043atai:OTFTechnologyMember2026-01-012026-03-310002081043atai:ResearchAndDevelopmentServicesRevenueMember2026-01-012026-03-310002081043atai:InnoplexusAgMemberatai:GabaTherapeuticsIncMember2025-12-310002081043us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002081043atai:SeriesCSharesMemberatai:EscrowAgreementMemberatai:BeckleyPsytechLimitedMember2024-01-030002081043atai:ResearchAndDevelopmentServicesRevenueMemberatai:CustomerTwoMember2026-01-012026-03-310002081043atai:AmandalaNeuroLimitedNotesReceivableMember2026-01-012026-03-310002081043atai:HerculesLoanAgreementMember2025-05-020002081043us-gaap:WarrantMemberatai:July2025PIPEFinancingMember2025-07-010002081043atai:ServiceAndPerformanceBasedOptionsMemberatai:TwoThousandAndTwentyIncentivePlanMember2025-12-310002081043atai:OtherMember2025-12-310002081043atai:GBelBucaManufacturingContractMember2026-03-310002081043atai:RizafilmMemberatai:SupplyAgreementMember2025-01-310002081043atai:StockPurchaseAndFrameworkAgreementMemberatai:DemerxMember2026-03-310002081043us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002081043atai:ContingentConsiderationLiabilityRelatedPartiesMember2026-01-012026-03-310002081043atai:OTFTechnologyMember2026-03-310002081043us-gaap:LeaseholdImprovementsMember2025-12-310002081043us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310002081043us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310002081043atai:TwentyTwentyIncentivePlanMember2026-01-012026-03-310002081043atai:PerceptionMember2026-03-310002081043atai:BeckleyPsytechLimitedMember2025-10-012025-12-310002081043us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002081043atai:BeckleyPsytechLimitedMember2026-03-310002081043us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:OtherExpensesMember2026-01-012026-03-310002081043us-gaap:WarrantMemberatai:BeckleyPsytechLimitedMember2024-05-310002081043atai:PerceptionMember2026-01-012026-03-310002081043atai:HerculesLoanAgreementMember2025-01-012025-03-310002081043atai:EleusisHoldingsLimitedMember2025-10-230002081043atai:AtaiLifeSciencesN.v.Member2025-09-300002081043atai:BeckleyPsytechLimitedMember2025-10-310002081043atai:BeckleyPsytechLimitedMemberatai:DeferredSharesMember2024-01-052024-01-050002081043us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310002081043us-gaap:ParentMember2025-12-310002081043atai:OtherMember2026-03-310002081043us-gaap:CommonStockMember2025-01-012025-03-310002081043atai:MeasurementInputProbabilityOfTheMilestoneMember2025-12-310002081043atai:ContingentConsiderationLiabilityMember2025-12-310002081043atai:AmandalaNeuroLimitedNotesReceivableMember2025-12-310002081043us-gaap:ResearchAndDevelopmentExpenseMemberatai:OptionsAndRestrictedStockAwardsMemberatai:AtaiEsopMember2025-01-012025-03-310002081043us-gaap:LicenseMember2025-01-012025-03-310002081043atai:AmandalaNeuroLimitedNotesReceivableMember2025-11-3000020810432024-12-310002081043atai:CompassPathwaysPlcMember2026-01-012026-03-310002081043us-gaap:ComputerEquipmentMember2025-12-310002081043us-gaap:CommonStockMember2025-01-012025-12-310002081043atai:BeckleyPsytechLimitedMemberatai:SubscriptionAndShareholdersAgreementMember2024-01-030002081043us-gaap:ResearchAndDevelopmentExpenseMemberatai:OptionsAndRestrictedStockAwardsMemberatai:AtaiEsopMember2026-01-012026-03-310002081043atai:PerceptionNeuroscienceHoldingsInc.Member2025-01-012025-12-310002081043atai:ServiceAndPerformanceBasedOptionsMemberatai:TwoThousandAndTwentyIncentivePlanMember2026-03-310002081043atai:ContingentConsiderationLiabilityRelatedPartiesMember2025-01-012025-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:ResearchAndDevelopmentServicesRevenueMember2026-01-012026-03-310002081043us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310002081043atai:ServiceAndPerformanceBasedOptionsMemberatai:TwoThousandAndTwentyIncentivePlanMember2025-01-012025-03-310002081043atai:NewNVNotesConversionFeatureMember2024-12-310002081043atai:PerceptionNeuroscienceHoldingsInc.Member2026-01-012026-03-310002081043atai:UnderwritingAgreementMemberus-gaap:CommonStockMember2025-10-310002081043us-gaap:RestrictedStockMember2026-01-012026-03-310002081043atai:GBelBucaManufacturingContractMember2026-01-012026-03-310002081043us-gaap:ComputerEquipmentMember2026-03-310002081043us-gaap:ParentMember2025-03-310002081043us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310002081043us-gaap:OfficeEquipmentMember2026-03-310002081043atai:ContingentConsiderationLiabilityRelatedPartiesMember2025-12-310002081043us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310002081043us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002081043us-gaap:ValuationTechniqueDiscountedCashFlowMemberatai:ContingentConsiderationLability-RelatedPartiesMemberatai:MeasurementInputProbabilityOfTheMilestoneMemberatai:DemerxMembersrt:MaximumMember2026-03-310002081043atai:SecondarySaleMemberatai:SeriesCSharesMemberatai:BeckleyPsytechLimitedMember2024-01-180002081043atai:ResearchAndDevelopmentServicesRevenueMember2025-03-310002081043us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-310002081043us-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMemberatai:PersonnelAndEmployeeRelatedExpensesMember2026-01-012026-03-310002081043atai:GabaTherapeuticsIncMember2026-03-310002081043us-gaap:RestrictedStockUnitsRSUMemberatai:BeckleyPsytechLimitedMember2025-11-052025-11-050002081043us-gaap:LicenseMember2026-01-012026-03-310002081043us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMemberatai:ContingentConsiderationLability-RelatedPartiesMemberatai:DemerxMembersrt:MaximumMember2026-03-310002081043us-gaap:ConvertibleDebtSecuritiesMember2025-01-012025-03-310002081043atai:VLS-01ExpensesMemberus-gaap:ReportableSegmentAggregationBeforeOtherOperatingSegmentMember2025-01-012025-03-310002081043us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310002081043us-gaap:OfficeEquipmentMember2025-12-310002081043atai:BeckleyPsytechMember2025-11-050002081043atai:MeasurementInputProbabilityOfTheMilestoneMember2026-03-31iso4217:EURxbrli:sharesatai:Bitcoiniso4217:EURiso4217:USDatai:Bitcoinxbrli:pureatai:Segmentutr:sqftxbrli:sharesiso4217:USDxbrli:sharesatai:CommonStockiso4217:USD\n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, DC 20549\n\n \n\n \n\nFORM 10-Q\n\n \n\n \n\n(Mark One)\n\n☒\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the quarterly period ended March 31, 2026 or\n\n☐\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\nFor the transition period from __________ to __________\n\n \n\nCommission File Number: 001-43037\n\n \n\n \n\nAtaiBeckley Inc.\n\n(Exact name of registrant as specified in its charter)\n\n \n\nDelaware\n\n41-3357923\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n(I.R.S. Employer\nIdentification No.)\n\nc/o atai Life Sciences US, Inc.\n\nc/o Industrious NYC\n\n250 West 34th Street\n\nNew York, New York\n\n10119\n\n(Address of principal executive offices)\n\n(Zip Code)\n\n \n\n(332) 282-0507\n\n(Registrant’s telephone number, including area code)\n\n \n\nN/A\n\n(Former name, former address and former fiscal year, if changed since last report)\n\n \n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\nTrading\n\nSymbol(s)\n\nName of each exchange\n\non which registered\n\nCommon stock, par value $0.01 per share\n\nATAI\n\nThe Nasdaq Stock Market LLC\n(Nasdaq Global Market)\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n\n \n\nEmerging growth company\n\n☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\nAs of May 8, 2026, the registrant had 368,166,674 shares of common stock, par value $0.01 per share, outstanding.\n\n \n\n \n\n \n\n \n\nATAIBECKLEY INC.\n\n \n\nFORM 10-Q\n\n \n\nTable of Contents\n\n \n\nPage\n\n[Forward-Looking Statements](#forward_looking_statements)\n\n1\n\nPART I. [FINANCIAL INFORMATION](#part_1_financial_information)\n\n3"}